My background is in virology and molecular biology. I have applied my expertise in the field of pan-cancer genomics. As an Assistant Professor in the Department of Radiation Medicine and Applied Sciences (RMAS) at the University of California, San Diego (UCSD), I am conducting genomics analysis to identify susceptibility targets for aggressive cancers. My bed-to-bench approach to studying real-world genomics paired with clinical data facilitates translational programs by helping overcome the limitations of experimental models for rapid translation into clinic. The overarching goal of my research program is to identify and validate actionable targets and new targetable mechanism for oncology diagnostic and therapeutic development. Prior to accepting the faculty position in November 2019, I worked closely with UCSD Moores Cancer Center leadership, the private sectors, and grant agencies to develop innovative translation programs initiated at our cancer center. I applied my scientific and business development background to support the experimental design for translational objectives and the fulfillment of pre-IND-required studies. I was directly involved in four programs that resulted in FDA approvals as well as high-visibility acquisitions. These included the development of Daurismo (glasdegib) in collaboration with Pfizer (approved in 2018) and the development of TG101348 in collaboration with TargeGen, which resulted in its acquisition by Sanofi followed by Impact Biomedicines. Later, it was acquired by Celgene/BMS in a $7 billion deal and FDA approval was granted for INREBIC (fedratinib). Also, during my tenure, the ROR1 licensing to Oncternal (clinical stage) materialized, and VelosBio was acquired by Merck in a $2.8 billion deal.